• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Hope for Treating the Most Infectious and Neglected Diseases

Paris, France / Geneva, Switzerland — 11 Jun 2008
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Today, the Paris-based Institut de Recherche pour le Développement (IRD) and DNDi announced the implementation of scientific cooperation projects for developing treatments against visceral leishmaniasis, Chagas disease, and sleeping sickness.
[Français]

One of these projects concerns group of quinolines molecules that reached the optimization phase, a step that represents a significant breakthrough to become a drug candidate.

©IRD/Baptiste Vergnesleismaniasis Leishmania parasites
infecting human macrophages

The IRD and the Drugs for Neglected Diseases initiative (DNDi), a non-profit product development partnership, have entered into two synergistic agreements to identify and develop new promising drug candidates against visceral leishmaniasis, Chagas disease and sleeping sickness.

This collaboration will allow the optimization and development of two chemical series of molecules: quinolines for visceral leishmaniasis and canthin-6-one alkaloids for Chagas disease. These series were identified by IRD scientific teams as having properties which could be translated into potential therapeutic efficacy.

These licensing agreements, which were granted by the IRD Expertise and Technology Transfert Department, will enable DNDi to develop its R&D portfolio and to enjoy the important knowledge of IRD researchers gained from their original work on the two chemical series. These molecules are the subject of patents owned by a joint cooperation of the IRD and CNRS in 2001(1), and the IRD and one of its partners from the South, the National University of Asuncion in Paraguay, in 2003(2).

“This agreement with the IRD allows us to expand our portfolio of promising compounds against neglected diseases and, in particular, to bring molecules active against trypanosomiasis and leishmaniasis into optimization phase,” said Denis Martin, DNDi’s Senior Project Manager in the R&D department.

With these two projects, the IRD will take advantage of the expertise, the know-how and the partners of DNDi’s consortium to develop molecules until their final stage throughout the various steps of the development of a new drug (pre-clinical and clinical phases).

Through this collaboration with DNDi, the IRD follows a long tradition of research on leishmaniasis, Chagas disease and sleeping sickness, and takes part in the Scientific Committee that will monitor this program. Several of its research units are currently working on these very neglected diseases: the “Knowledge of Tropical Plant Resources and their Usage”; “Hosts, Vectors, and Parasites Interaction in trypanosomiatidae Infections”; “Health of Mother and Children under Tropical Conditions”; “Characterization and Control of Populations of Vectors”; and “Pharmacochemistry of Natural Substances and Pharmacophores Redox” Units.

“These licensing agreements represent a major step forward in research and development
of new drugs against neglected diseases. With the collaboration with DNDi, the Quinolines and Canthin Projects will enter a phase of optimisation which is extremely encouraging
in relation to the urgent need of developing new medicines that are more effective, and more adapted against leishmaniasis and Chagas disease,” said Alain Fournet, the IRD’s Director of Research in the unit “Knowledge of Tropical Plant Resources and their Usage” (Biodival).

With 12 million people infected, leishmaniasis is a serious, life-threatening illness, endemic in 88 countries. Chagas disease (South American trypanosomiasis) affects 7 to 8 million people in 18 countries in Latin America, according to the WHO. These parasitic infections cause irreversible damage to various organs (heart, oesophagus, liver, spleen, colon…) and may be accompanied by high fever or anaemia. So far, few effective treatments against these diseases are made available.

©IRD/Christian Bellec No_Img Leishmania promastigote

DNDi
The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as malaria, leishmaniasis, human African trypanosomiasis, and Chagas disease. With the objective to address unmet patient needs for these diseases, DNDi was established in 2003 by Institut Pasteur and Médecins Sans Frontières along with four publicly-funded research organizations in neglected disease-endemic countries. Working in partnership with industry and academia, DNDi has the largest ever R&D portfolio for the kinetoplastid diseases and currently has 2 post-registration, 5 clinical, and 4 preclinical projects, along with a wide variety of discovery activities. In 2008, DNDi has delivered its first two products, fixed-dose antimalarial “ASAQ” and “ASMQ”. For further information, please consult www.dndi.org.

Institut de Recherche pour le Développement (IRD)
Created in 1944, the Paris-based Research Institute for Development is a public establishment of scientific and technological nature (EPST) with more than 2000 agents hired under the dual supervision of Ministries of Research and Cooperation, chaired by Mr. Jean-Francois Girard, State Councillor and headed by Professor Michel LAURENT.
The institute conducts research activities, expertise and training in Africa, Latin America, in Asia and Overseas French Tropical.

The IRD researchers are mainly devoted to studying biotopes and environment, sustainable management of living resources, society development and health. For more than sixty years, teams of researchers are present in the field and work together with countries of the South to strengthen their research capabilities. The IRD activities are conducted in close collaboration with its partners in the North and South. Involved in many European and international scientific programmes, it relies on AIRD* in mobilizing research organizations and universities for research and development.
*Inter-Agency body for Research for Development (IRD, CNRS, INSERM, Institut
Pasteur, CIRAD and CPU). www.ird.fr

(1) Patent n° PCT/FR2002/000140 du 17/01/2001 : Fakhfakh M., FigadèreI B., Fournet A., Franck X., Hocquemiller R., Prina E. “Substituted quinolines for the treatment of protozoan and retrovirus co-infections”.
(2) Patent n° PCT/FR2003/003459 du 25/11/2002 : Ferreira ME, Fournet A., Rojas de Arias A., Hocquemiller R., Poupon E. “Use of canthin-6-one, plant extracts containing same and derivatives thereof for the treatment of trypanosomiasis”.

For media inquiries

For more information, or to arrange an interview with Dr Bernard Pecoul or Denis Martin from DNDi, contact:
Sadia KAENZIG at skaenzig@dndi.org; +41 (0)79 819 9971; or
Ann-Marie SEVCSIK at amsevcsik@dndi.org; +41 (0)79 814 9147.

To arrange an interview with Alain Fournet from IRD, contact Gaëlle Courcoux; +33 (0) 1 48 03 75 19, presse@ird.fr

Partnership Chagas disease Visceral leishmaniasis

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo